What are the effects of estrogens on connective tissue disorders, specifically joint hypermobility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 12, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Estrogens can exacerbate joint hypermobility and connective tissue disorders by increasing tissue laxity and flexibility. Estrogen receptors are present in ligaments, tendons, and other connective tissues, and when activated, they can decrease collagen synthesis and increase the production of relaxin, which loosens connective tissues 1. This relationship explains why women, who typically have higher estrogen levels, are more prone to joint hypermobility conditions like Ehlers-Danlos syndrome and why symptoms often fluctuate during hormonal changes such as menstruation, pregnancy, and menopause.

Key Considerations

  • Estrogen therapy has been shown to increase bone density and reduce the risk of fractures, particularly in postmenopausal women 1.
  • However, the effects of estrogens on connective tissue disorders and joint hypermobility are complex and may involve both positive and negative effects on tissue laxity and flexibility.
  • The use of hormone replacement therapy (HRT) for the management of connective tissue disorders and joint hypermobility is not well established and requires careful consideration of the potential benefits and risks.

Management Strategies

  • Physical therapy focusing on joint stabilization, muscle strengthening, and proprioception training remains the cornerstone of management for hypermobility disorders, regardless of hormonal status.
  • Some clinicians may consider low-dose hormonal contraceptives with stable hormone levels rather than those with significant fluctuations for patients with hypermobility disorders.
  • Patients should work with both rheumatologists and endocrinologists when hormonal factors appear to significantly influence their joint hypermobility symptoms.

Prioritizing Outcomes

  • When managing patients with connective tissue disorders and joint hypermobility, it is essential to prioritize outcomes related to morbidity, mortality, and quality of life.
  • The potential benefits of estrogen therapy on bone density and fracture risk must be carefully weighed against the potential risks of exacerbating joint hypermobility and connective tissue disorders.

From the Research

Effects of Estrogens on Connective Tissue Disorders/Joint Hyper Mobility

  • The effects of estrogens on connective tissue disorders and joint hyper mobility can be understood through various studies, although direct evidence on joint hyper mobility is limited 2, 3.
  • Estrogen deprivation has a negative effect on connective tissue and its turnover, which can be prevented or reversed with estrogen therapy 2.
  • Estrogen therapy has been shown to have a positive effect on connective tissue in the skin dermis, bone matrix, carotid artery media, and intervertebral discs 2.
  • The impact of estrogen on connective tissue turnover has implications for maintaining tissue structure, aesthetic appearance, strength, stiffness, and the functioning of neighboring organs 2.
  • While there is no direct evidence on the effects of estrogens on joint hyper mobility, studies suggest that estrogen has profound effects on growth, differentiation, and function of many tissues, including bone and the cardiovascular system 3.
  • Tissue-specific estrogenic responses and molecular mechanisms are complex and involve the interaction of estrogen receptors with different DNA response elements and coregulator proteins 3.
  • Hormone replacement therapy (HRT) has been shown to have benefits in improving menopausal symptoms and potentially managing long-term sequelae, but its use must be carefully considered due to potential risks 4, 5.
  • The current recommendations for HRT use in menopausal women emphasize the importance of individualized treatment and consideration of patient-specific factors, such as age, time since menopause, and comorbidity status 4, 5.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Research

Effects of hormone replacement therapy on connective tissue: why is this important?

Best practice & research. Clinical obstetrics & gynaecology, 2009

4
Research

Hormone replacement therapy - Current recommendations.

Best practice & research. Clinical obstetrics & gynaecology, 2022

Related Questions

What is the treatment for menopause?
What are the considerations prior to starting Hormone Replacement Therapy (HRT) for women?
What is the most likely diagnosis for a postmenopausal woman with amenorrhea, vaginal atrophy, and insomnia?
What are the guidelines for long-term hormone replacement therapy (HRT) management?
Does Estrace (estradiol) cream require intravaginal insertion to be effective, or can it be applied topically to the peri-vaginal area?
What is the most likely cause of microcytic hypochromic anemia in a 1-year-old boy with a history of inadequate fruit and vegetable consumption, presenting with pallor, normal weight and height, and laboratory results showing low hemoglobin, microcytosis, and elevated reticulocytes?
What is Supraventricular Tachycardia (SVT) with aberrancy?
Does 15 grams of glucose correspond to 30 grams of sucrose, given that sucrose is composed of equal parts glucose and fructose?
What is the most likely cause of anemia in a 6-day-old girl with persistent jaundice, hemoglobin (Hb) of 12 g/dL, and reticulocytosis, with a negative Direct Coombs test and normal prenatal laboratory results for the mother with O+ (O positive) blood type?
Does treating hypoglycemia (low blood sugar) with 15 grams of glucose, when sucrose is administered, pose a risk of over-treatment due to its equal composition of glucose and fructose?
What laboratory abnormality is most likely associated with a 7-year-old boy presenting with fatigue, scleral icterus, and impaired renal function, following a recent episode of gastrointestinal (GI) symptoms, including abdominal pain, vomiting, diarrhea, and hematochezia (passage of blood in stool)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question